(Q53114197)

11 May 2018

title

Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. (English)

1 reference

11 May 2018

3

Andrea Mariani

1 reference

11 May 2018

Michaela E. McGree

4

object named as

Michaela E McGree

1 reference

11 May 2018

Amy L. Weaver

5

object named as

Amy L Weaver

1 reference

11 May 2018

author name string

Tina A Ayeni

1

1 reference

11 May 2018

Jamie N Bakkum-Gamez

2

1 reference

11 May 2018

Michael G Haddock

6

1 reference

11 May 2018

Gary L Keeney

7

1 reference

11 May 2018

Harry J Long

8

1 reference

11 May 2018

Sean C Dowdy

9

1 reference

11 May 2018

Karl C Podratz

10

1 reference

11 May 2018

language of work or name

English

0 references

publication date

25 March 2013

1 reference

11 May 2018

published in

Gynecologic Oncology

1 reference

11 May 2018

volume

129

1 reference

11 May 2018

issue

3

1 reference

11 May 2018

page(s)

478-485

1 reference

11 May 2018

Two pathogenetic types of endometrial carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Endometrial adenocarcinoma in Norway. A study of a total population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The Role of Adjuvant Radiotherapy in Carcinoma of the Endometrium—Results in 550 Patients with Pathologic Stage I Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Prognostic parameters of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The comparative assessment and improvement of quality of surgical care in the Department of Veterans Affairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

The role of surgical cytoreduction in Stage IV endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

Role of cytoreduction in stage III and IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

A proposed model for endometrial serous carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.03.011

10.1016/J.YGYNO.2013.03.011

7 January 2021

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

23535279

1 reference

11 May 2018